Transcript alskdfj - HIV Research Catalyst Forum

Beyond HAART
What comes
next?
Overview
• How far have we come in HIV since 1981?
Overview
• How far have we come in HIV since 1981?
• What are the shortcomings of the current
ARV regimens?
Overview
• How far have we come in HIV since 1981?
• What are the shortcomings of the current
ARV regimens?
• What are the key challenges in ARV
research?
Overview
• How far have we come in HIV since 1981?
• What are the shortcomings of the current
ARV regimens?
• What are the key challenges in ARV
research?
• How can activists help meet those
challenges?
Progress Since 1981
• Survival after diagnosis has gone from
months to decades.
• Projected lifespan of people with HIV is now
within 10 to 15 years of normal.
• Many people can now take meds once daily
& pill counts are dramatically smaller.
• Side effects remain, but are substantially
diminished since the late 1990s.
• Experts now think current meds suppress
nearly all HIV replication.
Lingering Problems
•
•
•
•
•
•
•
Treatment is currently life-long
Adherence a challenge for many
Residual inflammation is an issue
Many lack immunologic response
Short- and long-term toxicity
Multi-class drug resistance
High financial burden
Short- vs. Long-Term
Solutions
• Long-term solutions will likely require:
– Destroying latent reservoirs
– Improving immune control of virus
– Restoring the immune system
Short- vs. Long-Term
Solutions
• Long-term solutions will likely require:
– Destroying latent reservoirs
– Improving immune control of virus
– Restoring the immune system
But how long will this take?
In the mean-time
• Can we develop even less toxic drugs?
• Can we develop new drugs for people
with multi-class drug resistance?
• Can we develop formulations to improve
adherence?
• Can we prove that earlier treatment is
definitively better for all?
Rate of Discovery
HBV
HCV
HIV
Rate of Discovery
HBV
1967
HCV
1987
HIV
1983
Rate of Discovery
HBV
1967
HCV
1987
HIV
1983
Rate of Discovery
HBV
1967
HCV
1987
HIV
1983
Rate of Discovery
HBV
1967
HCV
1987
HIV
1983
Rate of Discovery
HBV
1967
HCV
1987
HIV
1983
New & Better Drugs: How?
• The FDA judges new drugs based on unmet
need. So, if you are a company how do you
fund and conduct research proving that your
drug:
– Suppresses virus better than others?
– Is less toxic both in the short and long-term?
– Works as well for people with multi-class drug
resistance?
– Enhances the immune response to treatment?
Advocacy Opportunities
Good places to start:
• Advocate for independent local HIV
treatment education
• Join local community advisory boards
• Join local IRB
• Join national community advisory
boards (NCAB, etc.)
• Advocate for ADAP & Medicaid
Advocacy Opportunities
Go deeper:
• Clinical trial design and review
• Advocate for funding for research
• Keep up public pressure for better treatments
and ultimately a cure.
• Get involved in—or start—coalitions to tackle
specific problems (e.g. aging, etc.)
• Advocate for lower drug prices.